[go: up one dir, main page]

DK3452485T3 - Arginasehæmmere og deres terapeutiske anvendelser - Google Patents

Arginasehæmmere og deres terapeutiske anvendelser Download PDF

Info

Publication number
DK3452485T3
DK3452485T3 DK17721137.2T DK17721137T DK3452485T3 DK 3452485 T3 DK3452485 T3 DK 3452485T3 DK 17721137 T DK17721137 T DK 17721137T DK 3452485 T3 DK3452485 T3 DK 3452485T3
Authority
DK
Denmark
Prior art keywords
therapeutic applications
arginase inhibitors
arginase
inhibitors
therapeutic
Prior art date
Application number
DK17721137.2T
Other languages
English (en)
Inventor
Adam Golebiowski
Karol Jedrzejczak
Krzysztof Matyszewski
Jacek Olczak
Roman Blaszczyk
Julita Nowicka
Bartlomiej Borek
Joanna Brzezinska
Anna Gzik
Marek Dziegielewski
Original Assignee
Oncoarendi Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Sa filed Critical Oncoarendi Therapeutics Sa
Application granted granted Critical
Publication of DK3452485T3 publication Critical patent/DK3452485T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17721137.2T 2016-05-04 2017-05-02 Arginasehæmmere og deres terapeutiske anvendelser DK3452485T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662331550P 2016-05-04 2016-05-04
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne
US201762444669P 2017-01-10 2017-01-10
PCT/EP2017/060413 WO2017191130A2 (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications

Publications (1)

Publication Number Publication Date
DK3452485T3 true DK3452485T3 (da) 2020-11-09

Family

ID=60190450

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17721137.2T DK3452485T3 (da) 2016-05-04 2017-05-02 Arginasehæmmere og deres terapeutiske anvendelser

Country Status (24)

Country Link
US (3) US10391077B2 (da)
EP (1) EP3452485B1 (da)
JP (1) JP6971477B2 (da)
KR (1) KR102374788B1 (da)
CN (1) CN109415387B (da)
AU (1) AU2017259887B2 (da)
BR (1) BR112018072545B1 (da)
CA (1) CA3022482C (da)
CL (1) CL2018003132A1 (da)
CO (1) CO2018013077A2 (da)
DK (1) DK3452485T3 (da)
ES (1) ES2834065T3 (da)
HR (1) HRP20201821T1 (da)
HU (1) HUE052468T2 (da)
IL (1) IL262387B (da)
LT (1) LT3452485T (da)
MX (1) MX378806B (da)
PE (1) PE20181924A1 (da)
PH (1) PH12018501976A1 (da)
PL (2) PL417066A1 (da)
SA (1) SA518400356B1 (da)
SG (1) SG11201807974QA (da)
SI (1) SI3452485T1 (da)
WO (1) WO2017191130A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027317T2 (en) 2010-10-26 2016-10-28 Mars Inc Boronates as arginase inhibitors
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
PT3368541T (pt) 2015-10-30 2020-07-06 Calithera Biosciences Inc Composições e métodos para inibição da atividade da arginase
WO2017155879A1 (en) 2016-03-07 2017-09-14 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
ES2970715T3 (es) 2016-12-22 2024-05-30 Prec Pharmaceuticals Inc Composiciones y métodos para inhibir la actividad de la arginasa
JOP20200197A1 (ar) 2018-02-17 2020-08-16 Astrazeneca Ab مثبطات أرجيناز وطرق لاستخدامها
SG11202008113RA (en) * 2018-03-05 2020-09-29 Arcus Biosciences Inc Arginase inhibitors
WO2019177873A1 (en) 2018-03-13 2019-09-19 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
AU2019246728A1 (en) 2018-03-29 2020-08-27 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
WO2019245890A1 (en) * 2018-06-20 2019-12-26 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
KR102718333B1 (ko) 2018-11-16 2024-10-17 아르커스 바이오사이언시즈 인코포레이티드 Arg1 및/또는 arg2의 억제제
WO2020131598A1 (en) * 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
CA3159783A1 (en) 2019-11-12 2021-05-20 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing ido antagonist prodrugs useful in treating of cancer and methods thereof
US20230140132A1 (en) * 2020-01-07 2023-05-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
US20240336635A1 (en) 2023-04-06 2024-10-10 Molecure S.A. Process for the production of (1r,2s,5r)-1-amino-5-[2-(dihydroxyboranyl)ethyl]-2-[(dimethylamino)methyl]-cyclohexane-1-carboxylic acid

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016192A1 (en) 1991-03-15 1992-10-01 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP1049660A1 (en) * 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
EP1604977A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals CIS pyrrolidinyl derivatives and their uses
EP1604978A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals Trans pyrrolidinyl derivatives and their pharmaceutical uses
WO2008061612A1 (en) 2006-11-21 2008-05-29 Rijksuniversiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
EP2389352B1 (en) 2009-01-26 2019-05-08 The Trustees Of The University Of Pennsylvania Arginase inhibitors and methods of use
JP5898177B2 (ja) 2010-04-22 2016-04-06 マーズ インコーポレイテッド アルギナーゼ阻害剤およびそれらの治療用途
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
HUE027317T2 (en) 2010-10-26 2016-10-28 Mars Inc Boronates as arginase inhibitors
CN103402549A (zh) 2010-12-31 2013-11-20 考瑞多制药公司 精氨酸酶抑制剂及其使用方法
MX343534B (es) 2011-10-19 2016-11-09 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
JP6152167B2 (ja) * 2012-04-18 2017-06-21 マーズ インコーポレイテッド アルギナーゼ阻害剤としての環拘束性類似体
WO2014009509A1 (en) 2012-07-13 2014-01-16 Janssen R&D Ireland Macrocyclic purines for the treatment of viral infections
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX385315B (es) 2015-06-23 2025-03-14 Calithera Biosciences Inc Composiciones y metodos para inhibir actividad de arginasa.
PT3368541T (pt) 2015-10-30 2020-07-06 Calithera Biosciences Inc Composições e métodos para inibição da atividade da arginase
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
CA3042878A1 (en) 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
CN111902532A (zh) 2018-01-28 2020-11-06 日内瓦大学 用于癌症治疗的精氨酸酶抑制

Also Published As

Publication number Publication date
AU2017259887A1 (en) 2018-09-27
KR102374788B1 (ko) 2022-03-15
SA518400356B1 (ar) 2022-01-19
BR112018072545A2 (pt) 2019-06-25
MX378806B (es) 2025-03-11
EP3452485A2 (en) 2019-03-13
WO2017191130A3 (en) 2017-12-14
JP6971477B2 (ja) 2021-11-24
IL262387B (en) 2021-10-31
CL2018003132A1 (es) 2019-02-22
US12053451B2 (en) 2024-08-06
US10391077B2 (en) 2019-08-27
US10912755B2 (en) 2021-02-09
LT3452485T (lt) 2020-12-28
SG11201807974QA (en) 2018-10-30
CN109415387B (zh) 2021-08-27
EP3452485B1 (en) 2020-09-09
NZ746211A (en) 2024-12-20
PL3452485T3 (pl) 2021-04-19
IL262387A (en) 2018-12-31
CN109415387A (zh) 2019-03-01
BR112018072545B1 (pt) 2022-08-23
HUE052468T2 (hu) 2021-04-28
AU2017259887B2 (en) 2022-03-17
PH12018501976A1 (en) 2019-07-01
US20170319536A1 (en) 2017-11-09
CO2018013077A2 (es) 2019-04-30
WO2017191130A4 (en) 2018-03-01
CA3022482C (en) 2024-06-11
KR20190015250A (ko) 2019-02-13
PL417066A1 (pl) 2017-11-06
JP2019518726A (ja) 2019-07-04
PE20181924A1 (es) 2018-12-11
HRP20201821T1 (hr) 2021-04-16
MX2018013387A (es) 2019-02-28
US20210260019A1 (en) 2021-08-26
ES2834065T3 (es) 2021-06-16
WO2017191130A2 (en) 2017-11-09
SI3452485T1 (sl) 2021-01-29
CA3022482A1 (en) 2017-11-09
US20190365701A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
DK3452485T3 (da) Arginasehæmmere og deres terapeutiske anvendelser
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3988117T3 (da) Terapeutiske antistoffer og deres anvendelser
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3464282T3 (da) Heteroarylsubstituerede pyridiner og fremgangsmåder til anvendelse
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
IL280863A (en) Autotaxin inhibitors and uses thereof
DK3548033T3 (da) Forbindelser og deres fremgangsmåde til anvendelse
DK3256218T3 (da) Kdm1a-hæmmer og anvendelse deraf i terapi
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3307727T3 (da) Heterocykliske inhibitorer af erk1 og erk2 og deres anvendelse i behandlingen af kræft
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
PL3240777T3 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
DK3621694T5 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3490988T3 (da) Ny forbindelse og fremgangsmåde
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3426243T3 (da) 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
DK3268374T3 (da) Kv1.3-inhibitorer og deres medicinske anvendelse
DK3595665T3 (da) Dobbelthæmmere af magl og faah
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf